While ER, PR, HER-2, and MIB1/Ki67 remain significant prognostic biomarkers in breast cancer, advanced technologies like wide next-generation sequencing (WNGS) have enabled the discovery of additional prognostic genes and signatures. This evidence concerns the gene ERBB2 and breast carcinoma.